Related information about Ruxolitinib Phosphate Tablets/Jiekewei

Ruxolitinib tablets/Ruxolitinib (Ruxolitinib) is a selective JAK1/2 inhibitor and a targeted therapy drug. It is mainly used for adults with myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD) in adults and children over 12 years of age. Myelofibrosis and polycythemia vera are diseases in which abnormal blood cell proliferation occurs due to abnormalities in bone marrow hematopoiesis. Patients may experience enlarged spleen, general fatigue, night sweats, and an increased risk of blood clots. Ruxolitinib controls disease progression and improves symptoms by inhibiting the JAK signaling pathway and reducing pro-inflammatory cytokines and abnormal blood cell proliferation signals.

Ruxolitinib is administered orally and can be used with or without food. The dose needs to be adjusted according to the type of disease and hematological indicators. Dosage in patients with myelofibrosis is determined based on platelet count and in patients with polycythemia vera based on hemoglobin, platelet, and neutrophil counts. The dose for patients with graft-versus-host disease also needs to be dynamically evaluated. Chronic GVHD usually takes a standard dose twice a day, while the starting dose for patients with acute GVHD is relatively low, which can be gradually increased under safety monitoring and slowly reduced according to the condition after 6 months of treatment. During treatment, if hematological indicators are abnormal or infection occurs, the dose should be adjusted or medication suspended in a timely manner to ensure patient safety.

In clinical application, ruxolitinib has shown significant efficacy and improvement in quality of life. While taking the drug, patients need to regularly review blood routine, liver and kidney function and infection indicators, and pay attention to possible adverse reactions, such as cytopenias, anemia, rash or mild to moderate infection. As a targeted drug, ruxolitinib provides long-term, stable and controllable treatment options for patients with myelofibrosis, polycythemia vera and GVHD by precisely regulating the JAK signaling pathway. Its targeted nature and safety make it a core drug in the treatment of these blood and immune-related diseases, bringing sustainable disease management and improvement in quality of life to patients.

Reference materials:https://www.jakavi.com/